0001628280-23-036466.txt : 20231102 0001628280-23-036466.hdr.sgml : 20231102 20231102170056 ACCESSION NUMBER: 0001628280-23-036466 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231031 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Baldry Mark CENTRAL INDEX KEY: 0001644137 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38295 FILM NUMBER: 231373406 MAIL ADDRESS: STREET 1: C/O AMICUS THERAPEUTICS STREET 2: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: X4 Pharmaceuticals, Inc CENTRAL INDEX KEY: 0001501697 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 273181608 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 BUSINESS PHONE: 857-529-8300 MAIL ADDRESS: STREET 1: 61 NORTH BEACON STREET STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02134 FORMER COMPANY: FORMER CONFORMED NAME: Arsanis, Inc. DATE OF NAME CHANGE: 20100920 4 1 wk-form4_1698958841.xml FORM 4 X0508 4 2023-10-31 0 0001501697 X4 Pharmaceuticals, Inc XFOR 0001644137 Baldry Mark C/O X4 PHARMACEUTICALS, INC. 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 0 1 0 0 Chief Commercial Officer 0 Common Stock 2023-10-31 4 A 0 34947 0 A 34947 D Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor. /s/ Adam S. Mostafa, attorney-in-fact 2023-11-02